XML 28 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
Common Stock
At The Market Offering One
Common Stock
At The Market Offering Two
Common Stock
Additional Paid-In Capital
At The Market Offering One
Additional Paid-In Capital
At The Market Offering Two
Additional Paid-In Capital
Accumulated Deficit
Cumulative effect adjustment for adoption of new accounting guidance
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Cumulative effect adjustment for adoption of new accounting guidance
At The Market Offering One
At The Market Offering Two
Total
Balance, beginning of period at Dec. 31, 2017     $ 4,000     $ 514,002,000 $ (474,000) $ (305,850,000) $ (76,000) $ (474,000)     $ 208,080,000
Balance, beginning of period (in shares) at Dec. 31, 2017     44,507,960                    
Statement of Stockholders' Equity (Deficit)                          
Issuance of common stock for repayment of notes payable           22,030,000             22,030,000
Issuance of common stock for repayment of notes payable (in shares)     636,526                    
Issuance of common stock $ 1,000     $ 48,493,000 $ 28,387,000           $ 48,494,000 $ 28,387,000  
Issuance of common stock (in shares) 1,429,205 1,107,000                      
Issuance of common stock for asset purchase agreement           1,942,000             1,942,000
Issuance of common stock for asset purchase agreement (in shares)     56,099                    
Exercise of stock options           10,328,000             10,328,000
Exercise of stock options (in shares)     749,294                    
Stock-based compensation expense     $ 0     26,598,000   0 0       26,598,000
Vesting of restricted common stock awards (in shares)     72,000                    
Vesting of employee restricted common stock and common stock subject to repurchase           4,000     47,000       4,000
Vesting Of Employee Restricted Common Stock And Common Stock Subject To Repurchase (in shares)     174,595                    
Purchase of common stock under benefit plans           680,000             680,000
Purchase of common stock under benefit plans (in shares)     26,272                    
Unrealized gain (loss) on marketable debt securities                         47,000
Net loss               (109,954,000)         (109,954,000)
Balance, end of period at Dec. 31, 2018     $ 5,000     652,464,000 $ 803,000 (416,278,000) (29,000) $ 803,000     236,162,000
Balance, end of period (in shares) at Dec. 31, 2018     48,758,951                    
Statement of Stockholders' Equity (Deficit)                          
Issuance of common stock       $ 116,356,000             $ 116,356,000    
Issuance of common stock (in shares) 4,341,428                        
Exercise of stock options           14,863,000             14,863,000
Exercise of stock options (in shares)     1,120,186                    
Stock-based compensation expense           27,243,000             27,243,000
Vesting of restricted common stock awards (in shares)     99,919                    
Purchase of common stock under benefit plans           620,000             620,000
Purchase of common stock under benefit plans (in shares)     35,314                    
Unrealized gain (loss) on marketable debt securities                 136,000       136,000
Net loss     $ 0         (133,746,000)         (133,746,000)
Balance, end of period at Dec. 31, 2019     $ 5,000     811,546,000   (549,221,000) 107,000       262,437,000
Balance, end of period (in shares) at Dec. 31, 2019     54,355,798                    
Statement of Stockholders' Equity (Deficit)                          
Issuance of common stock     $ 1,000     203,725,000             203,726,000
Issuance of common stock (in shares)     6,900,000                    
Exercise of stock options           19,500,000             19,500,000
Exercise of stock options (in shares)     964,412                    
Stock-based compensation expense           23,156,000             23,156,000
Vesting of restricted common stock awards (in shares)     304,638                    
Purchase of common stock under benefit plans           896,000             896,000
Purchase of common stock under benefit plans (in shares)     38,609                    
Unrealized gain (loss) on marketable debt securities                 (153,000)       (153,000)
Net loss               (115,976,000)         (115,976,000)
Balance, end of period at Dec. 31, 2020     $ 6,000     $ 1,058,823,000   $ (665,197,000) $ (46,000)       $ 393,586,000
Balance, end of period (in shares) at Dec. 31, 2020     62,563,457